General Information of the Drug (ID: M6APDG04156)
Name
SAR-113945
Synonyms
S-0100229; S-0100658
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D0AE3U
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for SAR-113945. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR-113945 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). [1], [2]
References
Ref 1 The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-KappaB/MYC signaling network. Oncogene. 2019 May;38(19):3667-3680. doi: 10.1038/s41388-019-0683-z. Epub 2019 Jan 18.
Ref 2 Inhibition of IKappaB phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45. doi: 10.1152/ajpheart.00290.2012. Epub 2012 Oct 5.